Reply to 'Safety profile of capecitabine as maintenance treatment after XELOX or FOLFOX in metastatic colorectal cancer patients' by C. Cremolini et al.

Luo, H Y; Xu, R H

Luo, H Y; Xu, R H.

Affiliation

Luo HY; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.
Xu RH; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China xurh@sysucc.org.cn.

Ann Oncol ; 27(9): 1810-1, 2016 09.

Article in En | MEDLINE | ID: mdl-27194813

Subject(s)

Capecitabine; Fluorouracil; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Deoxycytidine/analogs & derivatives; Fluorouracil/analogs & derivatives; Humans; Leucovorin; Organoplatinum Compounds; Oxaloacetates

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Capecitabine / Fluorouracil Limits: Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2016 Document type: Article Affiliation country: China

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google